Almirall acquires rights to distribute Alzheimer’s treatment in Spain for an initial €45 million
Bankinter| Laboratorios Almirall (ALM) has acquired the rights to distribute a product to treat Alzheimer’s disease in Spain. The agreement gives Almirall exclusive rights to a transdermal patch containing Rivastigmine to treat Alzheimer’s disease. The transaction has been closed for an upfront payment of €45 million and provides for additional potential compliance payments of up to €15 million. Assessment: Positive news, the company has been looking for acquisitions to strengthen…









